What is the appropriate enoxaparin (Lovenox) bridging regimen for a 150 kg patient on apixaban 5 mg twice daily with a recent deep‑vein thrombosis before a left heart catheterization?

Bridging Strategy for Left Heart Catheterization in Patient with Recent DVT

For this 150 kg patient with recent DVT on apixaban 5 mg BID, discontinue apixaban 48 hours before the left heart catheterization and do NOT use enoxaparin bridging therapy. 1

Rationale for No Bridging

The most recent perioperative guidelines explicitly state that heparin bridging (UFH or LMWH) is not needed except for very high thrombotic risk situations 1. Left heart catheterization is a moderate bleeding risk procedure that can be safely performed with appropriate apixaban interruption alone.

Key Evidence Against Bridging:

• The 2017 French GIHP guidelines clearly state: "There is no need for preoperative heparin bridging (UFH or LMWH) except for very thrombotic high-risk" 1
• The FDA apixaban label confirms: "Bridging anticoagulation during the 24 to 48 hours after stopping apixaban tablets and prior to the intervention is not generally required" 2
• The 2021 ACC Expert Consensus states that bridging with LMWH is associated with increased bleeding risk and should be reserved only for patients within 3 months of VTE or other thrombophilic states 3

Apixaban Interruption Protocol

Timing of Last Dose:

• Stop apixaban 48 hours before the procedure (last dose 2 days prior) 2
• This 48-hour window is appropriate for moderate bleeding risk procedures like cardiac catheterization 2
• The patient's renal function should be assessed using Cockcroft-Gault formula to confirm this timing is adequate 1

Critical Consideration - "Recent DVT":

If the DVT is in the acute phase (within first few weeks), this changes everything. The French guidelines specifically note: "If planned procedure should take place during the early phase of deep venous thrombosis...when high dose of rivaroxaban or apixaban are recommended, a personalized approach should be discussed by a multidisciplinary team" 1

• If DVT occurred <3 months ago AND is still in acute treatment phase (first 7 days when apixaban should be 10 mg BID), consider deferring the elective catheterization until completing acute treatment 3
• If DVT is 1-3 months old, the patient is at higher thrombotic risk, and bridging with therapeutic enoxaparin could be considered, though guidelines still don't mandate it 3

If Bridging Were Necessary (High-Risk Scenario Only)

Should the multidisciplinary team determine bridging is essential due to very recent DVT:

Enoxaparin Dosing for 150 kg Patient:

• Standard therapeutic dose: 1 mg/kg subcutaneous every 12 hours 4, 5, 6, 7
• For 150 kg: 150 mg subcutaneous every 12 hours
• Critical caveat: The FDA label notes "Optimal dose unclear in patients >120 kg" 4
• Consider anti-Factor Xa monitoring with target 0.6-1.0 IU/mL for therapeutic dosing 4, 7

Bridging Timeline (if used):

• Start enoxaparin when apixaban is stopped (48 hours pre-procedure)
• Last enoxaparin dose: 24 hours before catheterization 5, 6
• Resume apixaban 24-48 hours post-procedure once hemostasis confirmed 5, 6, 2

Post-Procedure Resumption

• Resume apixaban 24 hours after catheterization if hemostasis is adequate 2
• For higher bleeding risk or if hemostasis concerns exist, wait 48-72 hours 8
• Resume at the patient's usual maintenance dose (5 mg BID for long-term DVT prevention) 2

Common Pitfalls to Avoid

1. Do not reflexively bridge all patients with recent VTE - this increases bleeding risk without proven benefit in most cases 1, 3, 1
2. Do not use weight-capped enoxaparin dosing - if bridging is used, dose based on actual body weight with anti-Xa monitoring 9, 10, 11, 12
3. Do not restart apixaban too early - ensure adequate hemostasis first, particularly given the arterial access site 2
4. Assess renal function - at 150 kg, calculate CrCl to ensure apixaban clearance is adequate for standard timing 1